Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray Aitken

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Mhealth|March 16, 2017
Why life sciences companies need to tap technology to gain a competitive edge-and what that means for the chief information officers (CIO) roleMurray Aitken
Health Affairs (Project Hope)|May 6, 2015
Pharmaceutical innovation: the authors replyErnst R Berndt, Deanna Nass, Murray Aitken
Health Affairs (Project Hope)|December 18, 2008
Prescription drug spending trends in the United States: looking beyond the turning pointMurray Aitken, Ernst R Berndt, David M Cutler
Health Affairs (Project Hope)|February 4, 2015
Decline in economic returns from new drugs raises questions about sustaining innovationsErnst R Berndt, Deanna Nass, Michael Kleinrock, et al.
Drug Discovery Today|September 15, 2018
The future of drug development: the paradigm shift towards systems therapeuticsMeindert Danhof, Kevin Klein, Pieter Stolk, et al.
Health Affairs (Project Hope)|September 9, 2016
Has The Era Of Slow Growth For Prescription Drug Spending Ended?Murray Aitken, Ernst R Berndt, David Cutler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?Michael Kleinrock, Kimberly Westrich, Lisabeth Buelt, et al.
Clinical Therapeutics|August 4, 2020
Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction CoefficientDavid Cameron, Cara Willoughby, Denise Messer, et al.
PLOS Global Public Health|September 6, 2024
Global consumption patterns of combination hypertension medication: An analysis of pharmaceutical sales data from 2010-2021Sahan Jayawardana, Allen Campbell, Murray Aitken, et al.
Drug Discovery Today|April 1, 2022
Four scenarios for the future of medicines and social policy in 2030Hubert G Leufkens, Zuzana Kusynová, Murray Aitken, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Mhealth|March 16, 2017
Why life sciences companies need to tap technology to gain a competitive edge-and what that means for the chief information officers (CIO) roleMurray Aitken
Health Affairs (Project Hope)|May 6, 2015
Pharmaceutical innovation: the authors replyErnst R Berndt, Deanna Nass, Murray Aitken
Health Affairs (Project Hope)|December 18, 2008
Prescription drug spending trends in the United States: looking beyond the turning pointMurray Aitken, Ernst R Berndt, David M Cutler
Health Affairs (Project Hope)|February 4, 2015
Decline in economic returns from new drugs raises questions about sustaining innovationsErnst R Berndt, Deanna Nass, Michael Kleinrock, et al.
Drug Discovery Today|September 15, 2018
The future of drug development: the paradigm shift towards systems therapeuticsMeindert Danhof, Kevin Klein, Pieter Stolk, et al.
Health Affairs (Project Hope)|September 9, 2016
Has The Era Of Slow Growth For Prescription Drug Spending Ended?Murray Aitken, Ernst R Berndt, David Cutler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?Michael Kleinrock, Kimberly Westrich, Lisabeth Buelt, et al.
Clinical Therapeutics|August 4, 2020
Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction CoefficientDavid Cameron, Cara Willoughby, Denise Messer, et al.
PLOS Global Public Health|September 6, 2024
Global consumption patterns of combination hypertension medication: An analysis of pharmaceutical sales data from 2010-2021Sahan Jayawardana, Allen Campbell, Murray Aitken, et al.
Drug Discovery Today|April 1, 2022
Four scenarios for the future of medicines and social policy in 2030Hubert G Leufkens, Zuzana Kusynová, Murray Aitken, et al.
Pageof 2